Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
July 2018
-
Press Release
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is… -
Press Release
Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
Phase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo[1] Relapse-free survival benefit with… -
Press Release
Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million… -
Press Release
Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis
Novartis enters an exclusive license agreement with Galapagos and MorphoSys for an investigational biologic compound, MOR106, a novel antibody directed against IL-17C IL-17C is believed to… -
Press Release
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer… -
Key Release
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
Net sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD… -
Key Release
Novartis réalise une solide croissance au deuxième trimestre et poursuit sa transformation en une entreprise axée sur les médicaments
Hausse du chiffre d'affaires net de 5% (tcc[1], +7% USD), stimulée principalement par: Cosentyx, qui a progressé à USD 701 millions, (+40% tcc), enregistrant une forte croissance dans toutes ses… -
Key Release
Novartis erzielt im zweiten Quartal ein solides Wachstum und setzt die Transformation zu einem fokussierten Arzneimittelunternehmen fort
Der Nettoumsatz steigt um 5% (kWk[1], +7% USD), vor allem dank folgender Beiträge: Cosentyx erreicht USD 701 Millionen (+40% kWk) mit starken Zuwächsen bei allen Indikationen in den USA und der… -
Statement
Essential Consultants – Updates
-
Story Discovery
Drug development gets big data analytics boost
With Nerve Live, Novartis is harnessing the power of data for the benefit of patients.
June 2018
-
Key Release
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
First CHMP opinion for a CAR-T cell therapy in two distinct indications - DLBCL in adults and B-cell ALL in children Marketing Authorization Application (MAA) based on landmark global CAR-T… -
Key Release
Novartis erhält positive CHMP-Stellungnahme für Kymriah® zur Behandlung zweier aggressiver Blutkrebsarten - ein wichtiger medizinischer Fortschritt für Patientinnen und Patienten in Europa
Erste CHMP-Stellungnahme zu CAR-T-Zell-Therapie bei zwei verschiedenen Indikationen: DLBCL bei Erwachsenen und B-Zell-ALL bei Kindern Der Antrag auf Marktzulassung (MAA) basiert auf zwei…